Evidence map›Paper›PMID 25918230›Full record

ArticleDiabetes2015

A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes.

Ivonne Sluijs, Michael V Holmes, Yvonne T van der Schouw, Joline W J Beulens, Folkert W Asselbergs, José María Huerta, Tom M Palmer, Larraitz Arriola, Beverley Balkau, Aurelio Barricarte and 33 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. A machine learning-based framework for predicting type 2 diabetes mellitus using hematological indices.American heart journal plus : cardiology research and practice · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. The genetics of gout: translation into clinical practice.Therapeutic advances in musculoskeletal disease · 2025
    Review
  15. Review
  16. Review
  17. Observational
  18. Article
  19. SGLT2 Inhibitors and Uric Acid Homeostasis.Gout, urate, and crystal deposition disease · 2024
    Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 9 countries.

Ivonne SluijsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands i.sluijs-2@umcutrecht.nl.
Michael V HolmesClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Division of Transplantation and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Yvonne T van der SchouwJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Joline W J BeulensJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Folkert W AsselbergsJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands Department of Cardiology, Heart Long Institute, University Medical Center Utrecht, Utrecht, the Netherlands Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, the Netherlands.
José María HuertaDepartment of Epidemiology, Murcia Regional Health Council, Murcia, Spain CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Tom M PalmerDivision of Health Sciences, Warwick Medical School, University of Warwick, Coventry, U.K.
Larraitz ArriolaCIBER Epidemiología y Salud Pública (CIBERESP), Spain Public Health Division of Gipuzkoa, San Sebastian, Spain Instituto BIO-Donostia, Basque Government, San Sebastian, Spain.
Beverley BalkauInserm, Center for Research in Epidemiology and Population Health (CESP), U1018, Villejuif, France Université Paris-Sud, UMRS 1018, Villejuif, France.
Aurelio BarricarteCIBER Epidemiología y Salud Pública (CIBERESP), Spain Navarre Public Health Institute (ISPN), Pamplona, Spain.
Heiner BoeingGerman Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Françoise Clavel-ChapelonInserm, Center for Research in Epidemiology and Population Health (CESP), U1018, Villejuif, France Université Paris-Sud, UMRS 1018, Villejuif, France.
Guy FagherazziInserm, Center for Research in Epidemiology and Population Health (CESP), U1018, Villejuif, France Université Paris-Sud, UMRS 1018, Villejuif, France.
Paul W FranksLund University, Malmö, Sweden Umeå University, Umeå, Sweden.
Diana GavrilaDepartment of Epidemiology, Murcia Regional Health Council, Murcia, Spain CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Rudolf KaaksGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Kay Tee KhawUniversity of Cambridge, Cambridge, U.K.
Tilman KühnGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Esther Molina-MontesCIBER Epidemiología y Salud Pública (CIBERESP), Spain Andalusian School of Public Health, Granada, Spain.
Lotte Maxild MortensenDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
Peter M NilssonLund University, Malmö, Sweden.
Kim OvervadSection for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark Aalborg University Hospital, Aalborg, Denmark.
Domenico PalliCancer Research and Prevention Institute (ISPO), Florence, Italy.
Salvatore PanicoDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Olov RolandssonUmeå University, Umeå, Sweden.
Carlotta SacerdoteUnit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital, University of Turin and Center for Cancer Prevention (CPO), Turin, Italy Human Genetics Foundation (HuGeF), Turin, Italy.
Núria SalaUnit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, and Translational Research Laboratory, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Julie A SchmidtCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.
Robert A ScottMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Sabina SieriEpidemiology and Prevention Unit, Milan, Italy.
Nadia SlimaniInternational Agency for Research on Cancer, Lyon, France.
Annemieke M W SpijkermanNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Anne TjonnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.
Rosario TuminoASP Ragusa, Ragusa, Italy AIRE ONLUS, Ragusa, Italy.
Daphne L van der ANational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Stephen J SharpMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Nita G ForouhiMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Claudia LangenbergMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
Elio RiboliSchool of Public Health, Imperial College London, U.K.
Nicholas J WarehamMRC Epidemiology Unit, University of Cambridge, Cambridge, U.K.
InterAct Consortium
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESUniversity Medical Center Utrecht · NLAalborg University Hospital · DKCentre de recherche en Epidémiologie et Santé des Populations · FRLund University · SENational Institute for Public Health and the Environment · NLCentre International de Recherche sur le Cancer · FRDanish Cancer Society · DKFederico II University Hospital · ITGerman Cancer Research Center · DEGerman Institute of Human Nutrition · DEGobierno del Principado de Asturias · ESHeidelberg University · DEInstitut Català d'Oncologia · ESInternational Flame Research Foundation · ITItalian institute for Genomic Medicine · ITNational Centre for Disease Prevention and Control · ITNetherlands Heart Institute · NLPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUmeå University · SE

Funding

Cancer Research UK 16491Medical Research Council G0401527Medical Research Council G0802432Medical Research Council G1000143Medical Research Council MC_U106179471Medical Research Council MC_UP_A100_1003Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/5World Health Organization 001
6 · The paper itself

Abstract

We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid-associated loci. We used data of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident case subjects with type 2 diabetes were ascertained. Higher uric acid was associated with a higher diabetes risk after adjustment for confounders, with a hazard ratio (HR) of 1.20 (95% CI 1.11, 1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95% CI 15, 18) per SD increase and explained 4% of uric acid variation. By using the genetic score to estimate the unconfounded effect, we found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01 [95% CI 0.87, 1.16]). Including data from the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, increasing our dataset to 41,508 case subjects with diabetes, the summary odds ratio estimate was 0.99 (95% CI 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid-lowering therapies may therefore not be beneficial in reducing diabetes risk.

Indexed as

Genetic LociGenetic Predisposition to DiseaseAdultDiabetes Mellitus, Type 2FemaleHumansMaleMendelian Randomization AnalysisMiddle AgedProspective StudiesUric AcidUric Acid

Identifiers

PMID25918230
PMCPMC6284788
OpenAlexW2127975509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.